BeiGene (FRA:49BA) Total Liabilities : €2,080 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Total Liabilities?

BeiGene's Total Liabilities for the quarter that ended in Dec. 2023 was €2,080 Mil.

BeiGene's quarterly Total Liabilities declined from Jun. 2023 (€1,781.55 Mil) to Sep. 2023 (€1,650.66 Mil) but then increased from Sep. 2023 (€1,650.66 Mil) to Dec. 2023 (€2,079.71 Mil).

BeiGene's annual Total Liabilities declined from Dec. 2021 (€2,126.62 Mil) to Dec. 2022 (€1,884.16 Mil) but then increased from Dec. 2022 (€1,884.16 Mil) to Dec. 2023 (€2,079.71 Mil).

BeiGene Total Liabilities Historical Data

The historical data trend for BeiGene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Liabilities Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

570.54

1,423.31

2,126.62

1,884.16

2,079.71

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1,884.16	1,680.70	1,781.55	1,650.66	2,079.71

BeiGene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BeiGene's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1659.874	+	(201.62	+	157.699
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	46.765	+	13.75)
	=	2,080

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5323.437	-	3243.729
	=	2,080

BeiGene's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1659.874	+	(201.62	+	157.699
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	46.765	+	13.75)
	=	2,080

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	5323.437	-	3243.729
	=	2,080

BeiGene Total Liabilities Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines